WELCOME TO ONCOSCIENCE

About Us

Oncoscience GmbH develops therapeutic options for rare diseases in oncology.

CLICK HERE FOR MORE INFO


ONCOLOGY

Oncology and Orphan Drugs

Cancer is one of the leading causes of death worldwide and e.g. in Germany the second leading cause of death after cardiovascular diseases.

CLICK HERE FOR MORE INFO

NEWS

Specific Pharma A/S and Oncoscience GmbH launch a Named Patient Program for the treatment of cancer with nimotuzumab.

Oncoscience | November 6th, 2020

Specific Pharma announced today that it has entered into a supply and distribution collaboration with German based Onc...

Children with diffuse intrinsic pons glioma (DIPG) benefit from nimotuzumab

Oncoscience | March 25th, 2019

The results of an international clinical trial were published in March 2019. Forty-two children aged 3 to 20 years suffe...

Mawdsleys and Oncoscience launch a Named Patient Program for CIMAher® (Nimotuzumab) in the U.K. and Ireland

Oncoscience | October 3rd, 2018

Mawdsleys and Oncoscience GMbH have launched a Named Patient Supply Program to allow Oncologists in the United Kingd...